Abstract |
Alzheimer's disease (AD) is the most common dementia. No cure exists, and current treatment only manages early symptoms. Mitochondrial dysfunction is a hallmark of amyloid-β (Aβ) neurotoxicity, the pathogenic protein implicated in AD. This is due in part to the interaction between Aβ and amyloid-binding alcohol dehydrogenase (ABAD). This mitochondrial protein is a vital energy regulator that, following Aβ binding, activates signaling cascades that lead to neuronal death. One of the most significant roles of ABAD is to maintain the balance of estradiol/ estrone in neurons. However, the Aβ-ABAD interaction disrupts this balance and leads to a reduction in levels of estradiol, thus leading to an increase in reactive oxygen species levels and to apoptosis. Two additional proteins, peroxiredoxin-2 and endophilin-1, are implicated in Aβ-ABAD complex-mediated toxicity. Targeting the Aβ-ABAD interaction has emerged as a novel therapeutic strategy for AD. Herein, we review the chemistry and pharmacology of reported ABAD inhibitors.
|
Authors | Ahmed Morsy, Paul C Trippier |
Journal | Journal of medicinal chemistry
(J Med Chem)
Vol. 62
Issue 9
Pg. 4252-4264
(05 09 2019)
ISSN: 1520-4804 [Electronic] United States |
PMID | 30444369
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Amyloid beta-Peptides
- Enzyme Inhibitors
- 3-Hydroxyacyl CoA Dehydrogenases
- HSD17B10 protein, human
- PRDX2 protein, human
- Peroxiredoxins
- Acyltransferases
- 2-acylglycerophosphate acyltransferase
|
Topics |
- 3-Hydroxyacyl CoA Dehydrogenases
(antagonists & inhibitors, metabolism)
- Acyltransferases
(metabolism)
- Alzheimer Disease
(drug therapy)
- Amyloid beta-Peptides
(metabolism)
- Animals
- Cell Line
- Enzyme Inhibitors
(pharmacology, therapeutic use)
- Humans
- Mitochondria
(metabolism)
- Peroxiredoxins
(metabolism)
- Protein Binding
(drug effects)
|